Medy-Tox Inc. (KOSDAQ:086900)
141,800
+3,800 (2.75%)
Apr 1, 2025, 3:30 PM KST
Medy-Tox Revenue
In the year 2024, Medy-Tox had annual revenue of 228.62B KRW with 3.39% growth. Medy-Tox had revenue of 55.18B in the quarter ending December 31, 2024, a decrease of -18.86%.
Revenue
228.62B
Revenue Growth
+3.39%
P/S Ratio
4.42
Revenue / Employee
317.09M
Employees
721
Market Cap
944.31B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 228.62B | 7.50B | 3.39% |
Dec 31, 2023 | 221.12B | 26.02B | 13.34% |
Dec 31, 2022 | 195.10B | 10.23B | 5.53% |
Dec 31, 2021 | 184.87B | 44.04B | 31.27% |
Dec 31, 2020 | 140.83B | -65.07B | -31.60% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,547.32B |
Celltrion | 3,557.30B |
ALTEOGEN | 102.85B |
Yuhan | 2,067.79B |
SK Biopharmaceuticals | 547.60B |
HLB Co., Ltd. | 51.92B |
Sam Chun Dang Pharm. | 210.92B |
PharmaResearch | 350.12B |